Lupin arm unveils heart drug in Canada

Published On 2023-08-31 07:06 GMT   |   Update On 2023-10-07 10:57 GMT
Advertisement

Montreal: Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited has announced the launch of Propranolol LA (long-acting) capsules, 60 mg, 80 mg, 120 mg and 160 mg, in Canada.

Propranolol LA is a generic equivalent of Inderal LA, it provides an effective treatment solution since the discontinuation of Inderal LA for patients and healthcare practitioners.

The medicine is a beta-blocker used to treat hypertension, angina, tremors, heart rhythm disorders, and other heart or circulatory conditions.

Advertisement

"Propranolol LA’s launch caters to the needs of Canadian patients, reaffirming Lupin's commitment to enhancing healthcare access and affordability. The launch of Propranolol LA, the sole extended-release formulation of Propranolol accessible to Canadian patients following the discontinuation of Inderal LA, has led to significant progress in fulfilling patient unmet needs. This extended-release variant not only ensures consistent alleviation of symptoms but also enhances patient adherence and overall quality of life. Lupin encourages patients to consult healthcare practitioners or pharmacists regarding the transition to Propranolol LA," the Company stated.

“We are delighted to announce the launch of Propranolol LA capsules for patients in Canada. We have diligently worked to build our portfolio to include Propranolol LA ensuring patients have access to the essential medicines. This launch signifies our commitment to fostering healthcare solutions that truly make a difference,” said Dr. Sofia Mumtaz, President – Legal, Canada, Australia, and Japan, Lupin. 

Read also: Lupin bags USFDA okay for idiopathic pulmonary fibrosis drug Pirfenidone

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News